Generated by AI
Relmada Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for oncology and central nervous system disorders. Its current pipeline centers on product candidates designed to address areas of significant unmet medical need, including NDV-01 for non-muscle invasive bladder cancer and sepranolone for neurological and compulsivity-related conditions. The company also advances esmethadone, a novel NMDA receptor antagonist being evaluated for central nervous system indications such as major depressive disorder and other related disorders. Relmada Therapeutics Inc. operates as a research-driven drug developer, using targeted clinical programs to explore new treatment options across cancer, psychiatric, and neurological care. Headquartered in Coral Gables, Florida, the company remains focused on late-stage development of proprietary therapies intended to expand treatment possibilities in specialized disease areas.
Website2222 Ponce de Leon Blvd.
Coral Gables, FL, 33134
United States
The latest articles about RLMD.
Relmada Therapeutics (NASDAQ:RLMD) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time
Summary of Sep 11's posts. Generated by AI.
Summary of Mar 10's posts. Generated by AI.
I can sit through a biotech presentation and come away convinced that the company has discovered the answer to half the problems in modern medicine. The slides look terrific. The market opportunity is enormous.
Summary of Mar 10's posts. Generated by AI.
Investors talking about RLMD also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.